Hybio Pharmaceutical Co., Ltd. (300199.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 23.87

From 52W high−16.40%

Volume39.09M

Market capCNY 19.58B

P/E (TTM)535.5x

P/S (TTM)21.7x

Div yield—

Key dataSep 18, 2026

Open

CNY 23.87

From 52W high

−16.40%

Volume

39.09M

Market cap

CNY 19.58B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

108.4x

P/E (TTM)

535.5x

RSI (14)

51.5

MomentumView details →

1D Return

−4.03%

YTD Return

+31.28%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

535.5x

EV/EBITDA

108.4x

EV/Sales

23.5x

P/S (TTM)

21.7x

P/B (TTM)

23.0x

ProfitabilityView details →

Gross Margin

60.31%

Net Margin

9.89%

EBITDA Margin

21.70%

ROE (TTM)

12.75%

ROA (TTM)

2.81%

Asset Turnover

0.29x

GrowthView details →

Revenue YoY

+27.42%

EPS YoY

+197.71%

FCF YoY

—

Revenue CAGR 3Y

+11.12%

EPS CAGR 3Y

+120.00%

EBITDA YoY

—

MomentumView details →

1D Return

−4.03%

YTD Return

+31.28%

1Y Return

−2.65%

RSI (14)

51.5

vs 50D SMA

+1.73%

vs 200D SMA

+11.89%

Capital & dividendView details →

Debt/Equity

2.43x

Current Ratio

0.43x

Quick Ratio

0.21x

Div Yield

—

Div Rate

—

Div Growth 1Y

+100.00%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

955.53M

Net Income (TTM)

94.52M

Op. CF (TTM)

263.91M

Latest newsMore news →

Hanyu Pharmaceutical received acceptance notices from China's National Medical Products Administration for clinical trial applications of HY3003 injection, developed with Shenzhen Tanyun Zhitai Pharmaceutical Technology for weight-loss indications.11d ago

Hybio Pharmaceutical's subsidiary Gansu Chengji Biopharmaceutical received a drug registration certificate from China's National Medical Products Administration for carboprost tromethamine injection, a generic drug for treating postpartum hemorrhage, which will be launched for sale.14d ago

Similar companies

捷佳伟创300724.SZ 东岳硅材300821.SZ 京蓝科技000711.SZ 太钢不锈000825.SZ 惠城环保300779.SZ 中兵红箭000519.SZ Find similar companies →

Latest newsMore news →

Hanyu Pharmaceutical received acceptance notices from China's National Medical Products Administration for clinical trial applications of HY3003 injection, developed with Shenzhen Tanyun Zhitai Pharmaceutical Technology for weight-loss indications.11d ago Hybio Pharmaceutical's subsidiary Gansu Chengji Biopharmaceutical received a drug registration certificate from China's National Medical Products Administration for carboprost tromethamine injection, a generic drug for treating postpartum hemorrhage, which will be launched for sale.14d ago